[{"id":"415c095a-fdbb-4c01-9393-539ef53dc7d9","acronym":"SuRage-EB","url":"https://clinicaltrials.gov/study/NCT07092410","created_at":"2025-08-02T14:07:29.999Z","updated_at":"2025-08-02T14:07:29.999Z","phase":"Phase 4","brief_title":"Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib","source_id_and_acronym":"NCT07092410 - SuRage-EB","lead_sponsor":"SRH Wald-Klinikum Gera GmbH","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 101","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 08/01/2030","primary_completion_date":" 08/01/2030","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2025-07-29"},{"id":"1b1049ad-72e3-482d-a433-13cd63e6b89e","acronym":"UK-EnBiRiM","url":"https://clinicaltrials.gov/study/NCT07022457","created_at":"2025-06-21T13:21:55.578Z","updated_at":"2025-06-21T13:21:55.578Z","phase":"","brief_title":"UK ENcorafenib and BInimetinib Real-world Study in Melanoma","source_id_and_acronym":"NCT07022457 - UK-EnBiRiM","lead_sponsor":"Vitaccess Ltd","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/23/2025","start_date":" 06/23/2025","primary_txt":" Primary completion: 12/06/2027","primary_completion_date":" 12/06/2027","study_txt":" Completion: 12/06/2027","study_completion_date":" 12/06/2027","last_update_posted":"2025-06-15"},{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"1ee7d622-cdd0-4c14-a5ad-ff67b7a251a6","acronym":"NCI-2021-11793","url":"https://clinicaltrials.gov/study/NCT05111561","created_at":"2021-11-08T14:53:11.471Z","updated_at":"2025-02-25T13:40:41.596Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05111561 - NCI-2021-11793","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion","tags":["HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • ZEN-3694"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-21"},{"id":"876c2e70-4925-4835-9b88-46d9ace36858","acronym":"ComboMATCH Treatment Trial","url":"https://clinicaltrials.gov/study/NCT05564403","created_at":"2022-11-26T21:57:48.468Z","updated_at":"2025-02-25T13:41:17.315Z","phase":"Phase 2","brief_title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05564403 - ComboMATCH Treatment Trial","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MAPK1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/09/2024","start_date":" 02/09/2024","primary_txt":" Primary completion: 01/21/2026","primary_completion_date":" 01/21/2026","study_txt":" Completion: 01/21/2026","study_completion_date":" 01/21/2026","last_update_posted":"2025-02-21"},{"id":"fb4d840f-ccf1-4e5e-ac00-2c10191c007e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554367","created_at":"2022-09-26T14:56:10.119Z","updated_at":"2025-02-25T13:54:43.263Z","phase":"Phase 2","brief_title":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554367","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • RAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Mektovi (binimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 08/26/2026","primary_completion_date":" 08/26/2026","study_txt":" Completion: 08/26/2026","study_completion_date":" 08/26/2026","last_update_posted":"2025-02-20"},{"id":"67d8f3e4-e0d4-4a45-8037-56a61f36875b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554354","created_at":"2022-09-26T14:56:09.831Z","updated_at":"2025-02-25T15:20:02.561Z","phase":"Phase 2","brief_title":"Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05554354","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • NF1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-12"},{"id":"f5887694-2af2-431c-9929-09e65d372e4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05355701","created_at":"2022-05-02T12:57:00.809Z","updated_at":"2025-02-25T15:35:37.767Z","phase":"Phase 1","brief_title":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","source_id_and_acronym":"NCT05355701","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mektovi (binimetinib) • claturafenib (PF-07799933)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/05/2022","start_date":" 07/05/2022","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 03/26/2028","study_completion_date":" 03/26/2028","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"152d28df-5166-4844-8189-63865407b89e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05954546","created_at":"2023-07-20T23:10:56.186Z","updated_at":"2025-02-25T16:46:55.104Z","phase":"","brief_title":"A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings","source_id_and_acronym":"NCT05954546","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 07/21/2023","start_date":" 07/21/2023","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-05"},{"id":"d0abf381-bbfa-4b21-bbe7-740e5caad62b","acronym":"BEAVER","url":"https://clinicaltrials.gov/study/NCT03839342","created_at":"2021-01-18T18:57:15.711Z","updated_at":"2025-02-25T16:59:56.947Z","phase":"Phase 2","brief_title":"Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations","source_id_and_acronym":"NCT03839342 - BEAVER","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRAF • KIAA1549","pipe":" | ","alterations":" BRAF mutation • BRAF V600K • BRAF fusion","tags":["BRAF • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600K • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"5b5025e1-918a-44f3-b1e4-127e110ec295","acronym":"","url":"https://clinicaltrials.gov/study/NCT05026983","created_at":"2021-08-30T21:53:02.254Z","updated_at":"2025-02-25T17:30:53.797Z","phase":"Phase 2","brief_title":"Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases","source_id_and_acronym":"NCT05026983","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/27/2021","start_date":" 12/27/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-01-30"},{"id":"ad4f690b-b51c-4f70-aa01-5da5b0887bb4","acronym":"CEBBRA","url":"https://clinicaltrials.gov/study/NCT06207656","created_at":"2024-01-17T16:18:48.040Z","updated_at":"2025-02-25T16:11:23.465Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer","source_id_and_acronym":"NCT06207656 - CEBBRA","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 04/01/2029","primary_completion_date":" 04/01/2029","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-10-21"},{"id":"7ae39bae-f74c-4bd9-bb9c-b0ac08141f45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04892017","created_at":"2021-05-19T15:52:38.986Z","updated_at":"2024-07-02T16:34:26.607Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors","source_id_and_acronym":"NCT04892017","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" KRAS • BRAF • NRAS • NF1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Lumakras (sotorasib) • Mektovi (binimetinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-06-13"},{"id":"2b720bdb-c868-4015-be63-be0574eeacf1","acronym":"PORTSIDE","url":"https://clinicaltrials.gov/study/NCT05926960","created_at":"2023-07-03T17:09:32.633Z","updated_at":"2024-07-02T16:34:59.560Z","phase":"Phase 2","brief_title":"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","source_id_and_acronym":"NCT05926960 - PORTSIDE","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 05/23/2025","primary_completion_date":" 05/23/2025","study_txt":" Completion: 05/23/2027","study_completion_date":" 05/23/2027","last_update_posted":"2024-06-03"},{"id":"db82afaa-1da0-4791-94e2-92a3b0bc6788","acronym":"BECOME-MB","url":"https://clinicaltrials.gov/study/NCT04074096","created_at":"2021-01-18T19:57:18.686Z","updated_at":"2025-02-25T16:09:27.668Z","phase":"Phase 2","brief_title":"Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis","source_id_and_acronym":"NCT04074096 - BECOME-MB","lead_sponsor":"UNICANCER","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/05/2022","start_date":" 09/05/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2029","study_completion_date":" 04/15/2029","last_update_posted":"2024-06-03"},{"id":"037452f4-ed9d-4921-b399-661395ba3e8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04913285","created_at":"2021-06-04T14:53:23.677Z","updated_at":"2024-07-02T16:35:00.535Z","phase":"Phase 1","brief_title":"A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors","source_id_and_acronym":"NCT04913285","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF • NRAS","pipe":" | ","alterations":" BRAF mutation • NRAS mutation","tags":["BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • exarafenib (KIN-2787)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 12/07/2024","primary_completion_date":" 12/07/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-29"},{"id":"a4fa2c9b-d0d8-45aa-8666-8374568e8a92","acronym":"EBIN","url":"https://clinicaltrials.gov/study/NCT03235245","created_at":"2021-01-18T15:59:13.644Z","updated_at":"2024-07-02T16:35:00.361Z","phase":"Phase 2","brief_title":"Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib","source_id_and_acronym":"NCT03235245 - EBIN","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 271","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 10/24/2023","primary_completion_date":" 10/24/2023","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-29"},{"id":"7f2b6ae3-35ab-4144-9fdd-b8dfede43457","acronym":"STARBOARD","url":"https://clinicaltrials.gov/study/NCT04657991","created_at":"2021-01-19T20:41:58.558Z","updated_at":"2024-07-02T16:35:03.047Z","phase":"Phase 3","brief_title":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","source_id_and_acronym":"NCT04657991 - STARBOARD","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 189","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-17"},{"id":"7d24d9e1-4dcb-42b7-a602-4f6bcfc0236d","acronym":"InCITe","url":"https://clinicaltrials.gov/study/NCT03971409","created_at":"2021-01-18T19:32:12.157Z","updated_at":"2024-07-02T16:35:04.267Z","phase":"Phase 2","brief_title":"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer","source_id_and_acronym":"NCT03971409 - InCITe","lead_sponsor":"Hope Rugo, MD","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-13"},{"id":"8ab2b8cb-11b1-4979-b5ca-712d9486d2c4","acronym":"the HOPE trial","url":"https://clinicaltrials.gov/study/NCT04132505","created_at":"2021-01-18T20:11:03.473Z","updated_at":"2024-07-02T16:35:04.080Z","phase":"Phase 1","brief_title":"Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT04132505 - the HOPE trial","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-13"},{"id":"35578b77-debc-4758-a26f-f1466ba8198e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439344","created_at":"2021-01-18T21:22:13.852Z","updated_at":"2024-07-02T16:35:05.015Z","phase":"Phase 2","brief_title":"Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)","source_id_and_acronym":"NCT04439344","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 05/31/2016","start_date":" 05/31/2016","primary_txt":" Primary completion: 05/03/2019","primary_completion_date":" 05/03/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-05-08"},{"id":"8d11e7de-5fd7-49f6-b0e9-31e7346e7fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04800822","created_at":"2021-03-16T14:52:26.431Z","updated_at":"2024-07-02T16:35:06.982Z","phase":"Phase 1","brief_title":"PF-07284892 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04800822","lead_sponsor":"Pfizer","biomarkers":" ALK • ROS1 • NF1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive","tags":["ALK • ROS1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 06/18/2024","primary_completion_date":" 06/18/2024","study_txt":" Completion: 11/29/2025","study_completion_date":" 11/29/2025","last_update_posted":"2024-04-30"}]